As Biotechnology businesses, BioTime Inc. (NYSEAMERICAN:BTX) and Celyad SA (NASDAQ:CYAD), are affected by contrast. This especially applies to their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioTime Inc. 4.99M 36.30 45.99M -0.58 0.00
Celyad SA N/A 0.00 N/A -7.01 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for BioTime Inc. and Celyad SA.

Profitability

Table 2 provides us the return on assets, net margins and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
BioTime Inc. -921.64% -54.6% -51%
Celyad SA 0.00% 0% 0%

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for BioTime Inc. and Celyad SA.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioTime Inc. 0 0 0 0.00
Celyad SA 0 0 1 3.00

On the other hand, Celyad SA’s potential upside is 135.05% and its consensus target price is $46.

Insider and Institutional Ownership

The shares of both BioTime Inc. and Celyad SA are owned by institutional investors at 45.1% and 6.89% respectively. Insiders owned roughly 0.8% of BioTime Inc.’s shares. On the other hand, insiders owned about 0.09% of Celyad SA’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioTime Inc. -2.5% -17.02% -2.88% -40.61% -42.59% 28.15%
Celyad SA 2.74% -2.78% -20.78% -31.6% -47.84% 15.64%

For the past year BioTime Inc.’s stock price has bigger growth than Celyad SA.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Celyad SA, a biopharmaceutical company, focuses on engineered cell therapy treatments. It operates in two segments, Cardiology and Immuno-oncology. The companyÂ’s lead product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure. Its lead product candidate in oncology disease is CAR-T NKR-2, an autologous chimeric antigen receptor (CAR) for the treatment of cancer. In addition, the companyÂ’s preclinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection catheter; heart access sheaths; mitral valve neo-chordaes; and closure devices. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *